Xceleron and Organon sign microdose study agreement

UK-based contract research organisation Xceleron has revealed a collaboration with Organon, the human healthcare business unit of Netherlands-based Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development.

The three selected drug candidates are all compounds from Organon' gynaecological R&D activities. The purpose of the human microdose study is to assess all important pharmacokinetic properties of the compounds, while confirming the scalability of the microdose to pharmacological dose for these compounds.

Xceleron will use its Accelerator Mass Spectrometry analytical technology to determine human plasma concentrations after microgram administration of the various drug candidates.

Xceleron' founder and CEO Professor Colin Garner said: "We are delighted that Organon has further demonstrated its willingness to adopt innovative approaches to drug development and are proud to add them to Xceleron' rapidly growing, international portfolio of human microdose supporters."